Expanding the clinicopathological spectrum of BAP1 mutated ccRCC: a study of 84 cases in multi-center cohort
In brief
An 84-case study identifies six patterns of BAP1-mutated kidney cancer
In a three-center review of 84 BAP1-mutated clear cell kidney cancers, researchers identified six tissue patterns; macroacinar and mixed patterns were most common. More than 65% of tumors in each cohort were high grade, consistent with an aggressive cancer type. The classification could aid diagnosis, but its value in guiding treatment or predicting outcomes remains unclear.
- Journal
- Human pathology (Q1)
- Published
- 1 October 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Neng-Qiao Wen, Xing-Si Peng, Chan Huang, Feng Chen, Ding-Kang Wang, Dan-Dan Zheng, et al.
- PMID
- 42822734
- DOI
- 10.1016/j.humpath.2026.106276
Why clinicians should know about it
- Picked for Pathology and Forensic Medicine (paper of the day, 2 October 2026): BAP1‑mutated ccRCC morphology, pathology spectrum
Abstract
AIMS: Somatic BAP1 mutations drive a distinct and aggressive subtype of clear cell renal cell carcinoma (ccRCC), but its full histomorphological spectrum remains unclear due to small sample sizes in previous studies. This study aimed to comprehensively characterize BAP1-mutated ccRCC, define its morphological subtypes in a multi-center cohort. METHODS AND RESULTS: A retrospective multi-center study was performed including 84 BAP1-mutated ccRCC cases from three cohorts, 16 from Sun Yat-sen University Cancer Center (SYSUCC), 38 from TCGA-KIRC, and 30 from CPTAC-ccRCC. Truncating mutations were the predominant BAP1 mutation type across all cohorts, accounting for 68.8% in SYSUCC, 60.5% in TCGA-KIRC, and 60.0% in CPTAC-ccRCC. Six distinct morphological subtypes were identified (Classic ccRCC, Macroacinar, Papillary, Sarcomatoid/Rhabdoid, Trabecular, and Mixed), with Macroacinar and Mixed subtypes being the most prevalent. 50% of Mixed subtype cases were a combination of Papillary and Macroacinar subtypes. All SYSUCC cases showed complete nuclear BAP1 loss in tumor cells by IHC, accompanied by predominantly diffuse-strong AMACR (P504S) immunostaining. Over 65% of cases in each cohort had high nuclear grade (G3/G4), with progression rates of 37.5% in the SYSUCC cohort, 39.5% in the TCGA-KIRC cohort, and 23.8% in the CPTAC-ccRCC cohort, respectively. For the entire cohort, the median overall survival (OS) was 73.8 months and median disease-free survival (DFS) was 63.8 months. CONCLUSIONS: This study clarifies the clinicopathological and morphological features of BAP1-mutated ccRCC and defines six distinct morphological subtypes. These findings expand the clinicopathological spectrum of this aggressive ccRCC subset, provide a standardized morphological classification for clinical diagnosis.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.